Drugs by active ingredient › Neomycin Sulfate + Nystatin + Thiostrepton + Triamcinolone Acetonide

Monthly reports by species, five years

Reports by the month FDA received them. Each panel has its own scale; the peak month is printed at the top right. The newest months are incomplete because FDA posts reports with a delay of three to six months.

Reports by year received

2026 covers reports received through March 2026 only.

Signs listed in reports

share of neomycin sulfate + nystatin + thiostrepton + triamcinolone acetonide reports listing the termall drugs containing thiostreptonall dog reports

1. Deafness29.1%276
2. Vomiting9.1%86
3. Loss of hearing7.7%73
4. Lethargy[unusually tired or inactive]6.2%59
5. Temporary deafness5.7%54
6. Lack of efficacy - NOS[the product did not have the expected effect]5.5%52
7. PR-ear(s), lesion(s)[legacy FDA term: lesions found in the ears]4.4%42
8. Diarrhoea[diarrhea]3.8%36
9. Partial deafness3.1%29
10. Pruritus[itching]2.7%26
11. Anorexia[not eating]2.5%24
12. Ataxia[unsteady, uncoordinated movement]2.4%23
13. Death2.4%23
14. Other abnormal test result NOS[abnormal laboratory result, type not specified]2.4%23
15. Ear discharge2.3%22
16. Elevated alanine aminotransferase (ALT)[a liver enzyme above the normal range]2.3%22
17. Accidental exposure[exposure that was not intended]2.2%21
18. Application site alopecia[hair loss where the product was applied]2.2%21
19. Behavioural disorder NOS[behaviour change, type not specified]2.2%21
20. Medication error NOS[a mistake in giving the product, type not specified]2.2%21
21. Not eating2.2%21
22. Death by euthanasia[the animal was euthanized]2.1%20
23. Emesis[vomiting]2.1%20
24. Skin lesion NOS[NOS: not otherwise specified]2.1%20
25. Seizure NOS[seizure, type not specified]1.8%17
26. Weight loss1.8%17
27. Decreased appetite1.7%16
28. Depression[dull, quiet or withdrawn]1.7%16
29. Polydipsia[drinking more than usual]1.7%16
30. Abnormal cytology1.6%15

Top 30 of 769 coded terms (VeDDRA, the veterinary reporting dictionary; plain-language gloss in brackets). One report can list several terms. The ticks show how often the same term appears in a wider pool of reports; they describe the reports, and FDA cautions that such figures cannot be used to estimate risk or to compare one product with another. openFDA masks brand and manufacturer names in adverse event records, so the reports counted here cannot be attributed to a particular brand.

Outcomes and report types

Coloured bar: reports naming neomycin sulfate + nystatin + thiostrepton + triamcinolone acetonide. Grey bar: all 1,357,245 reports in the database. Outcomes are the status at the time of the last report, as stated by the reporter; a report covering several animals can carry more than one outcome. FDA has not necessarily determined whether any drug played a part in any outcome.

Species and breeds in the reports

Breed shares follow how common each breed is. Crossbred animals and reports with no breed stay in the species figure only.

Age, weight and route

Route of administration stated in reports: auricular (otic) (347), topical (210), oral (10), cutaneous (3), ophthalmic (3), other (3).

In context

The thiostrepton pool is every report naming thiostrepton alone or in any combination; this combination accounts for 80% of it. Shares are of reports, not of animals treated. The number of doses sold is not public, so none of these figures is a rate of occurrence, and differences between columns reflect which animals receive a drug and who reports as much as anything else.

Other ingredient sets sharing an ingredient

Listed for navigation, ordered by report count. FDA states that these data "cannot be used to estimate the risk associated with the product or compare one drug or device product with another": drugs differ in formulation, in the animals they are given to, in sales volume and in years on the market. A report's ingredient field can be incomplete, so reports about one product may sit under more than one set.

Where this comes from. Counts are built from the openFDA Animal & Veterinary adverse event bulk files released 28 Sep 2026, which hold reports FDA's Center for Veterinary Medicine received through 31 Mar 2026. openFDA masks brand and manufacturer names in these files, so drugs are counted by the active ingredients each record discloses and no figure is attributed to a brand, application or company. Ingredient names, and the separate reference lists of approved products, follow the FDA Green Book as of 1 Oct 2026. Drug entries are grouped by the active ingredients their unmasked ingredient field discloses; the application number that records also carry is not used. No report text, lot numbers or reporter details are published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.